News Release

Prescription fills for semaglutide products

JAMA Health Forum

Peer-Reviewed Publication

JAMA Network

About The Study: The number of prescriptions filled for semaglutide has increased substantially, reaching 2.6 million prescriptions filled at retail pharmacies by December 2023. While Ozempic persistently accounted for most semaglutide fills, increases were considerably greater for Wegovy since its approval for weight loss in June 2021. These increases, which primarily occurred following increased awareness of weight-loss benefits in late 2022, are likely contributing to the FDA-reported shortage of Ozempic and Wegovy first issued in March 2022. Despite the disproportionate burden of obesity in Medicaid and Medicare Part D populations, and recent increases in public spending on weight-loss medications, most Wegovy fills were for the commercially insured.

Corresponding Author: To contact the corresponding author, Dima M. Qato, PharmD, MPH, PhD, email qato@usc.edu.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamahealthforum.2024.2026)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2024.2026?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=080224

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.